NASDAQ:ARCT - Arcturus Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.28 -0.23 (-3.06 %)
(As of 04/23/2019 04:00 PM ET)
Previous Close$7.51
Today's Range$7.14 - $7.50
52-Week Range$4.11 - $10.00
Volume47,076 shs
Average Volume77,827 shs
Market Capitalization$78.33 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. The company was founded in 2013 and is headquartered in San Diego, California.

Receive ARCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARCT
CUSIPN/A
Phone858-900-2660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.75 million
Book Value$1.27 per share

Profitability

Miscellaneous

Employees72
Market Cap$78.33 million
Next Earnings Date6/17/2019 (Estimated)
OptionableOptionable

Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Ltd (NASDAQ:ARCT) announced its quarterly earnings results on Monday, March, 18th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.41. The biotechnology company earned $7.58 million during the quarter, compared to analyst estimates of $3.59 million. View Arcturus Therapeutics' Earnings History.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, June 17th 2019. View Earnings Estimates for Arcturus Therapeutics.

What price target have analysts set for ARCT?

7 brokers have issued 12-month target prices for Arcturus Therapeutics' stock. Their predictions range from $15.00 to $18.00. On average, they anticipate Arcturus Therapeutics' stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 126.6% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics.

What is the consensus analysts' recommendation for Arcturus Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics.

What are Wall Street analysts saying about Arcturus Therapeutics stock?

Here are some recent quotes from research analysts about Arcturus Therapeutics stock:
  • 1. According to Zacks Investment Research, "Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. " (4/16/2019)
  • 2. HC Wainwright analysts commented, "Our 12-month, $30 price target on shares of Synthorx is based on a 12-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.5, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.2%, and tax rate of 15% beginning in FY 2029. We assign a 9% POS for THOR-707, which we anticipate could be developed in NSCLC, RCC, melanoma, and urothelial cancer. These indications together represent about 95% of our target with NSCLC being the biggest driver of valuation, elaborated upon subsequently." (4/5/2019)
  • 3. WBB Securities analysts commented, "Mesoblast announced continued positive survival data for remestemcel-L (allogeneic cell therapy) in children with steroid refractory acute graft vs. host disease (aGvHD). The next step for the company is meeting with FDA to discuss BLA submission. The cell therapy is already approved in Japan (as TEMCELL HS Inj) for aGvHD, licensed to JCR Pharmaceuticals Co Ltd (TYO: 4552 – NR)." (9/20/2018)

Has Arcturus Therapeutics been receiving favorable news coverage?

News articles about ARCT stock have been trending positive on Tuesday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arcturus Therapeutics earned a news impact score of 2.7 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.

Who are some of Arcturus Therapeutics' key competitors?

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Opko Health (OPK), Terravia (TVIAQ), Energy Transfer LP Unit (ET), KLA-Tencor (KLAC), Obsidian Energy (OBE), Amicus Therapeutics (FOLD), Idera Pharmaceuticals (IDRA), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD) and Abbott Laboratories (ABT).

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the folowing people:
  • Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 47)
  • Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 40)
  • Mr. Andrew H. Sassine, CFO & Director (Age 55)
  • Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
  • Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $7.28.

How big of a company is Arcturus Therapeutics?

Arcturus Therapeutics has a market capitalization of $78.33 million and generates $15.75 million in revenue each year. The biotechnology company earns $-21,780,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.

What is Arcturus Therapeutics' official website?

The official website for Arcturus Therapeutics is http://www.arcturusrx.com.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 Science Center Drive Suite 250, San Diego CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]


MarketBeat Community Rating for Arcturus Therapeutics (NASDAQ ARCT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  536
MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Vote "Outperform" if you believe ARCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Featured Article: Cost of Goods Sold (COGS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel